<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00416533</url>
  </required_header>
  <id_info>
    <org_study_id>CCCWFU-85302</org_study_id>
    <secondary_id>CDR0000466318</secondary_id>
    <secondary_id>CCCWFU-BG04-264</secondary_id>
    <secondary_id>AVENTIS-CCCWFU-85302</secondary_id>
    <nct_id>NCT00416533</nct_id>
  </id_info>
  <brief_title>Docetaxel, Doxorubicin, and Prednisone in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy</brief_title>
  <official_title>A Phase II Study of Taxotere (Docetaxel) Plus Adriamycin (Doxorubicin) and Prednisone (TAP) in Hormone-Refractory Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as docetaxel, doxorubicin, and prednisone, work&#xD;
      in different ways to stop the growth of tumor cells, either by killing the cells or by&#xD;
      stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill&#xD;
      more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving docetaxel, doxorubicin, and&#xD;
      prednisone together works in treating patients with advanced prostate cancer that has not&#xD;
      responded to hormone therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Assess prostate specific antigen response rate to docetaxel, doxorubicin hydrochloride,&#xD;
           and prednisone in patients with hormone-refractory advanced prostate cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Assess if treatment with docetaxel, doxorubicin hydrochloride, and prednisone will&#xD;
           improve health-related quality of life of these patients.&#xD;
&#xD;
        -  Assess the toxicity of docetaxel, doxorubicin hydrochloride, and prednisone.&#xD;
&#xD;
        -  Assess response rate in measurable disease.&#xD;
&#xD;
      OUTLINE: Patients receive docetaxel IV over 1 hour on day 1, doxorubicin hydrochloride IV&#xD;
      over 15 minutes on days 1 and 8, and oral prednisone once daily on days 1-21. Treatment&#xD;
      repeats every 21 days for at least 3 courses in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Quality of life is assessed at baseline, on day 1 of each course, after completion of 3&#xD;
      courses, and at disease progression.&#xD;
&#xD;
      After completing study treatment, patients are followed every 6 months for 1 year.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 47 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">47</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate with any of the following:&#xD;
&#xD;
               -  Prostate-specific antigen ≥ 10 mg/dL&#xD;
&#xD;
               -  Bone disease&#xD;
&#xD;
               -  Bidimensional soft tissue disease&#xD;
&#xD;
               -  Evaluable disease&#xD;
&#xD;
          -  Advanced disease AND failed prior primary androgen ablation therapy, including&#xD;
             anti-androgen withdrawal&#xD;
&#xD;
          -  Disease not amenable to local curative treatment&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Creatinine &lt; 2.0 mg/dL&#xD;
&#xD;
          -  SGPT and SGOT &lt; 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin ≤ ULN&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
          -  Ejection fraction ≥ 50%&#xD;
&#xD;
          -  Peripheral neuropathy ≤ grade 1&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No previous history of or concurrent malignancy, except for any of the following:&#xD;
&#xD;
               -  Inactive nonmelanoma skin cancer&#xD;
&#xD;
               -  Disease-free for five or more years&#xD;
&#xD;
               -  Adequately treated stage I or II cancer from which patient is currently in&#xD;
                  complete remission&#xD;
&#xD;
          -  No other serious medical illness that would limit survival to less than 3 months&#xD;
&#xD;
          -  No psychiatric condition that would prevent informed consent&#xD;
&#xD;
          -  No active, uncontrolled bacterial, viral, or fungal infection&#xD;
&#xD;
          -  No hemorrhagic disorder&#xD;
&#xD;
          -  No history of severe hypersensitivity reaction to other drugs formulated with&#xD;
             polysorbate 80&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No new hormonal treatment within the past 4 weeks&#xD;
&#xD;
          -  No prior immunotherapy, chemotherapy, or bone-seeking radiopharmaceuticals (e.g.,&#xD;
             strontium chloride Sr 89 or samarium Sm 153 lexidronam pentasodium)&#xD;
&#xD;
          -  Prior bisphosphonates allowed&#xD;
&#xD;
          -  At least 2 weeks since prior radiotherapy&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank M. Torti, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>December 27, 2006</study_first_submitted>
  <study_first_submitted_qc>December 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2006</study_first_posted>
  <last_update_submitted>January 17, 2017</last_update_submitted>
  <last_update_submitted_qc>January 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>adenocarcinoma of the prostate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

